BDNF Release and Signaling are Required for the Antidepressant Actions of GLYX-13
Sign Up to like & getrecommendations! Published in 2017 at "Molecular psychiatry"
DOI: 10.1038/mp.2017.220
Abstract: Conventional antidepressant medications, which act on monoaminergic systems, display significant limitations, including a time lag of weeks to months and low rates of therapeutic efficacy. GLYX-13 is a novel glutamatergic compound that acts as an… read more here.
Keywords: signaling required; antidepressant actions; release; actions glyx ... See more keywords